Suppr超能文献

酵母中衣壳蛋白L1自组装病毒样颗粒的优化、表征、比较以及针对人乳头瘤病毒52型的反向疫苗学设计

Optimization, characterization, comparison of self-assembly VLP of capsid protein L1 in yeast and reverse vaccinology design against human papillomavirus type 52.

作者信息

Firdaus Moh Egy Rahman, Mustopa Apon Zaenal, Ekawati Nurlaili, Chairunnisa Sheila, Arifah Rosyida Khusniatul, Hertati Ai, Irawan Shasmita, Prastyowati Anika, Kusumawati Arizah, Nurfatwa Maritsa

机构信息

Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Bogor, 16911, Indonesia.

Current Address: Laboratory of Structural Virology, The International Institute of Molecular Mechanisms and Machines (IMOL), Polish Academy of Sciences, Warsaw, Poland.

出版信息

J Genet Eng Biotechnol. 2023 May 24;21(1):68. doi: 10.1186/s43141-023-00514-9.

Abstract

BACKGROUND

Vaccination is the one of the agendas of many countries to reduce cervical cancer caused by the Human papillomavirus. Currently, VLP-based vaccine is the most potent vaccine against HPV, which could be produced by a variety of expression systems. Our study focuses on a comparison of recombinant protein expression L1 HPV52 using two common yeasts, Pichia pastoris and Hansenula polymorpha that have been used for vaccine production on an industrial scale. We also applied bioinformatics approach using reverse vaccinology to design alternative multi-epitope vaccines in recombinant protein and mRNA types.

RESULTS

Our study found that P. pastoris relatively provided higher level of L1 protein expression and production efficiency compared to H. polymorpha in a batch system. However, both hosts showed self-assembly VLP formation and stable integration during protein induction. The vaccine we have designed exhibited high immune activation and safe in computational prediction. It is also potentially suitable for production in a variety of expression systems.

CONCLUSION

By monitoring the overall optimization parameter assessment, this study can be used as the basis reference for large-scale production of the HPV52 vaccine.

摘要

背景

疫苗接种是许多国家减少人乳头瘤病毒所致宫颈癌的议程之一。目前,基于病毒样颗粒(VLP)的疫苗是针对人乳头瘤病毒最有效的疫苗,可通过多种表达系统生产。我们的研究重点是比较使用两种常用于工业规模疫苗生产的常见酵母——毕赤酵母和多形汉逊酵母来表达重组蛋白L1 HPV52。我们还应用了反向疫苗学的生物信息学方法来设计重组蛋白和mRNA类型的替代性多表位疫苗。

结果

我们的研究发现,在分批系统中,与多形汉逊酵母相比,毕赤酵母相对能提供更高水平的L1蛋白表达和生产效率。然而,两种宿主在蛋白诱导过程中均显示出病毒样颗粒的自组装形成和稳定整合。我们设计的疫苗在计算预测中表现出高免疫激活且安全。它也可能适用于多种表达系统的生产。

结论

通过监测整体优化参数评估,本研究可为大规模生产HPV52疫苗提供基础参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/10209368/54f7b1d00271/43141_2023_514_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验